Reporting rates of rhabdomyolysis with statins to the FDA

被引：0
|
作者：
机构：
来源：
Reactions Weekly | 2002年 / 898卷 / 1期
关键词：
Statin; Digoxin; Simvastatin; Atorvastatin; Pravastatin;
D O I：
10.2165/00128415-200208980-00008
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：4 / 4
相关论文
共 50 条
  • [1] Statins and the risk of rhabdomyolysis
    Rosenson, RS
    JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION, 2002, 25 (07) : 577 - 577
  • [2] Estimating the extent of reporting to FDA: a case study of statin-associated rhabdomyolysis
    McAdams, Mara
    Staffa, Judy
    Dal Pan, Gerald
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2008, 17 (03) : 229 - 239
  • [3] Statins, myalgia, and rhabdomyolysis
    Tournadre, Anne
    JOINT BONE SPINE, 2020, 87 (01) : 37 - 42
  • [4] Statins: rhabdomyolysis and myopathy
    Vu, D
    Murty, M
    McMorran, M
    CANADIAN MEDICAL ASSOCIATION JOURNAL, 2002, 166 (01) : 85 - 86
  • [5] Statins and the risk of rhabdomyolysis
    R. S. Rosenson
    Journal of Endocrinological Investigation, 2002, 25 : 577 - 577
  • [6] Rhabdomyolysis associated with concomitant use of colchicine and statins in the real world: identifying the likelihood of drug-drug interactions through the FDA adverse event reporting system
    Zhang, Sha
    Yan, Ming-Ming
    Zhao, Hui
    Qiu, Xiao-Yan
    Zhu, Deqiu
    FRONTIERS IN PHARMACOLOGY, 2024, 15
  • [7] Rhabdomyolysis Associations with Antibiotics: A Pharmacovigilance Study of the FDA Adverse Event Reporting System (FAERS)
    Teng, Chengwen
    Baus, Courtney
    Wilson, James P.
    Frei, Christopher R.
    INTERNATIONAL JOURNAL OF MEDICAL SCIENCES, 2019, 16 (11): : 1504 - 1509
  • [8] Statins: risk of fatal rhabdomyolysis
    Reactions Weekly, 2002, 890 (1) : 2 - 2
  • [9] Cholesterol Deficiency, Statins and Rhabdomyolysis
    Haines, Thomas H.
    BIOPHYSICAL JOURNAL, 2010, 98 (03) : 327A - 327A
  • [10] Statins: risk of rhabdomyolysis and myopathy
    Reactions Weekly, 2002, 886 (1) : 2 - 2
12345